[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[PVS] Biomarkers Conference 2008



Title: Biomarkers2008

Biomarkers 2008
Discovery, Validation and Application of Biomarker Technology

17TH – 19TH MARCH 2008, LONDON, UK


Industry leaders you will meet at the event include:

- Dr Hans Winkler, Senior Director, Translational Research Oncology, Johnson and Johnson
- Dr Paul Whiting, Head of Biomarkers & Translational Biology, Pfizer
- Professor Ian Wilson, Senior Principal Scientist, AstraZeneca
- Andrew Doherty, Director of Research Alliances, UCB
- Dr Christian Czech, CNS Research, Roche
- Dr Dave Moskowitz, CEO, Genomed
- Anna Rossi, Section Head, Toxicology & Drug Disposition, Organon
- Alastair Kent, Director, Genetic Interest Group
- Dr Alison Banham, Nuffield Department of Clinical Laboratory Sciences, University of Oxford
- Professor William M. Gallagher, Associate Professor of Cancer Biology, UCD Conway Institute, University College Dublin, Co-Founder, OncoMark Limited

The pharmaceutical industry is constantly looking for ways to cut costs, speed drugs to market and develop innovative new products to improve patient care. Biomarker technology can help your company achieve these three key goals. Yet despite the benefits biomarker technology has the potential to accrue, it is not yet widely applied. Successful application could give your company the competitive advantage it seeks, and this conference will help identify areas where biomarkers can be implemented in your business practices.

Reasons you cannot afford to miss this event:
- Identify areas where biomarker technology can increase the efficiency of your clinical trial process.
- Understand the potential for biomarkers in developing personalised medicine. How will this change the existing big pharma business model? Prepare your business to more fully integrate these operational and organisational changes.
- Discuss the latest biomarker assay developments and methods of clinical validation.
- Gain a deeper understanding of the growing biomarker industry. Who are the key players? What are the next developments? Where can you make the best alliance?

As the traditional blockbuster business model falters in its tracks, recently illustrated by Pfizer’s difficulties with Exubera, it seems the industry is shifting towards portfolios of personalised medicines. These can only be developed with the aid of biomarkers.

It is a new and exciting technology, which still has a lot of scope for innovative business applications. Methods of discovery are constantly evolving; as scientists begin to fully understand the potential of genomics, the whole scope of proteome analysis opens up before them. Applications for these new discoveries are still being explored and a major challenge is now faced in convincing the regulators.

This three day Visiongain conference will explore the business applications and regulatory considerations necessary for you to realize the potential biomarkers have for your business.
Places at this global forum are by invitation only. The Biomarkers Conference is an important step in the development of the personalised medicine, as members of the industry meet and benefit from the forum of open discussion and networking. It is by tackling problems together that we hope to see greater success in this market.

I look forward to meeting you at the conference

====================================================================
17th March 2008
Interactive 1-day workshop

Implementing gene expression based drug response profiling in clinical trials
Led by: Bastiaan van der Baan, Director, Business Development, Agendia
====================================================================

 Conference Agenda

Day One 18th March 2008

09:30 Registration and refreshments

10:00 Opening address from the chair
Dr Dave Moskowitz, CEO, Genomed

10:10 Adapting your business for biomarkers
• Does the use of biomarkers herald the end of the blockbuster drug model?
• Adjusting your business
- New roles
- Governance structures
• Overcoming the traditional attitudes to phase differentiation
Dr Paul Whiting, Head of Biomarkers & Translational Biology, Pfizer

10:50 Outsourcing biomarker research
• External partnerships vs internal capabilities
• Choosing where to outsource
- What to look for in a partner
- Planning division of responsibility
• Collaborating with academia
Andrew Doherty, Director of Research Alliances, UCB

11:30 Morning refreshments

11:50 Utilising bioinformatics in biomarker discovery
• Developing a ‘fit-for-purpose’ system
• Ensuring statistical value and avoiding false discovery rates
• Setting meaningful thresholds for identification

12:30 Quantitative, specific and spatial identification of protein modifications as biomarkers
• Targeted therapeutics directed at signaling pathways demand specific biomarker readouts
• The specificity of reagents employed to interrogate signaling pathways by immunohistochemistry is typically inadequate
• There is a need for quantitative and spatially resolved biomarker readouts
Professor Peter Parker, Head of The Division of Cancer Studies, King’s College London

13:00 Networking lunch

14:20 Predispostion SNPs: Biomarkers of choice
• Genetic statisticians vs genomic epidemiologists
• The failure of ‘neutral markers’ to fund success with any polygenic disease
• The successes of functional SNP markers
- Identifi cation of genes in the earliest stages of tumorigenesis
- Identifying the earliest circulating markers in the disease process
Dr Dave Moskowitz, CEO, Genomed

15:00 Application of metabolic profiling in biomarker discovery
• Metabolites as biomarkers of disease, efficacy and toxicity.
• Methodologies for profiling and biomarker discovery
• Animal model to clinical trial - applications and challenges
• Gaining new insights - metabolites to systems.
Professor Ian Wilson, Senior Principal Scientist, AstraZeneca

15:40 Afternoon refreshments

16:00 Developing safe and effective therapies for unmet medical needs
• Participation of patients and families in the process of undertaking clinical research
• The selection of relevant endpoints – what are the risks and benefi ts?
• Using biomarkers as a staging post in the development of safe and effective therapies for unmet medical needs – the perspective of patients and their families
Alastair Kent, Director, Genetic Interest Group

16:40 Translating patient selection markers for clinical application
• Discovery of markers for selection of patients with increased likelihood to benefit from treatment
• Assay development
• Assessment of clinical utility
• Application for streamlining early clinical development
• Development of theranostics
Dr Hans Winkler, Senior Director, Translational Research Oncology, Johnson and Johnson

17:20 Closing remarks from the chair

17:30 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting.


====================================================================

Day Two 19th March 2008
09:30 Registration and refreshments

10:00 Opening address from the chair
Dr Dave Moskowitz, CEO, Genomed

10:10 Identification, validation and application of efficacy biomarkers in the development of novel anti-cancer agents

10:50 Identification and validation of novel lymphoma biomarkers
• The clinical need for additional lymphoma biomarkers
• Diagnostic biomarkers to define disease subtypes and facilitate early diagnosis
• Prognostic markers to identify high-risk patients
• Biomarkers as therapeutic targets
• The relevance of lymphoma biomarkers in other malignancies
Dr Alison Banham, Nuffield Department of Clinical Laboratory Sciences, University of Oxford

11:30 Morning refreshments

11:50 Tissue microarray and digital slide scanning technology: application to cancer and oxicological biomarker development
• Tissue microarrays as translational research tools
• Bridging from discovery to validation in the omic era
• Manual and automated image analysis
• Case studies in cancer and toxicology
Professor William M. Gallagher, Associate Professor of Cancer Biology, UCD Conway Institute, University College Dublin, Co-Founder, OncoMark Limited

12:30 Use of biomarkers for safety assessment
• Validating toxicity biomarkers
• Detecting toxicity at a lower concentrations earlier on
• Using biomarkers to create an effective dosing regime at an earlier stage of clinical trials
• Improving pharmacovigilence
Anna Rossi, Section Head, Toxicology & Drug Disposition, Organon

13:10 Networking lunch

14:30 Using biomarkers for cancer therapeutics
• Finding good quality biomarkers
• Gene expression data vs Proteomics: which is the more valuable for developing accurate oncology biomarkers.
• Lessons learnt from Herceptin – is this the way forward for cancer treatment?

15:10 Biomarker for Alzheimer’s disease: strategy for identification and validation of new markers
• Targets and models for disease modification in Alzheimer’s disease
• Technologies for biomarker identification
• Strategies for biomarker validation
• Biochemical markers for diagnosis and disease progression in Alzheimer’s disease
Dr Christian Czech, CNS Research, Roche

15:50 Afternoon refreshments

16:10 Presentation to be announced

16.50 Panel Discussion: What does the future hold for biomarker technology?
• How will advances in proteomics affect biomarkers? Will it overtake genetic methods of biomarker discovery?
• Repositioning drugs on the market; what are the longer term industry implications?
• Moving towards personalized medicine

17:30 Chair’s closing remarks

17:40 End of conference

 

 

 

As a valued contact or customer of Visiongain, you are receiving this eNewsletter with information that we believe will be relevant to you.

If, however, you do not wish to receive future messages, please reply to this message, typing unsubscribe' in the subject box of your email.
Please allow 48hours to remove your email address.Thank you very much for your cooperation.


***Booking your place***


2 day Conference only ticket -
available for only GBP
£1299

All 3 days conference and workshop - available for only GBP £1699

If you would like to send more than 1 person then take advantage of the 3 for 2 offer. Send 3 people but only pay for 2.


Registration is simple!

All you need to do to book your place is contact Justyna.
You can either call me on
TEL: +44 (0)207 549 9946
or email:
justyna.drozdzal@visiongainglobal.com

Please feel free to contact me should you have any questions, or wish to book a place.
I look forward to meeting you at the event.

Kind Regards
Justyna Drozdzal